NCT02006628View on ClinicalTrials.gov

A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 25, 2014

Primary Completion Date

January 8, 2015

Study Completion Date

January 8, 2015

Conditions
SchizophreniaSchizophrenia-related Psychotic Disorder
Interventions
DRUG

Placebo

Placebo oral solution (0 milligrams \[mg\]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.

DRUG

GWP42003

GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.

Trial Locations (14)

130086

Târgovişte

540096

Târgu Mureş

550082

Sibiu

41-250

Czeladź

80-952

Gdansk

25-103

Kielce

20-831

Lublin

43-100

Tychy

54-235

Wroclaw

010825

Bucharest

041914

Bucharest

KT16 0AE

Chertsey

CV2 2TE

Coventry

SE5 8AF

London

Sponsors
All Listed Sponsors
lead

Jazz Pharmaceuticals

INDUSTRY